# Study Guide: 2022 AHA/ACC/HFSA Heart Failure Management This study guide provides a comprehensive synthesis of the "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure." It is designed to assist clinicians and students in mastering the contemporary evidence-based approach to preventing, diagnosing, and managing heart failure (HF). --- ## Core Concepts and Frameworks ### 1. The Stages of Heart Failure The 2022 guideline emphasizes a progressive model of HF development, revising the terminology for early stages to prioritize prevention and early intervention. | Stage | Revised Terminology | Definition and Criteria | | :--- | :--- | :--- | | **Stage A** | **At Risk for HF** | Patients at risk but without current/previous symptoms, structural heart disease, or cardiac biomarkers of stretch/injury (e.g., hypertension, diabetes, obesity, exposure to cardiotoxins). | | **Stage B** | **Pre-HF** | Patients without symptoms or signs of HF but with evidence of structural heart disease, increased filling pressures, or increased levels of natriuretic peptides or cardiac troponin. | | **Stage C** | **Symptomatic HF** | Patients with structural heart disease and current or previous symptoms of HF. | | **Stage D** | **Advanced HF** | Marked HF symptoms interfering with daily life; recurrent hospitalizations despite attempts to optimize guideline-directed medical therapy (GDMT). | ### 2. Classification by Left Ventricular Ejection Fraction (LVEF) HF is categorized based on LVEF, as this dictates the prognosis and the appropriate response to pharmacological and device-based treatments. | Type of HF | Abbreviation | LVEF Criteria | Additional Requirements | | :--- | :--- | :--- | :--- | | **Reduced EF** | **HFrEF** | $\le 40\%$ | — | | **Improved EF** | **HFimpEF** | $> 40\%$ | Previously $\le 40\%$; requires follow-up measurement. | | **Mildly Reduced EF** | **HFmrEF** | $41\%–49\%$ | Evidence of increased LV filling pressures (e.g., elevated natriuretic peptides). | | **Preserved EF** | **HFpEF** | $\ge 50\%$ | Evidence of increased LV filling pressures (spontaneous or provokable). | ### 3. Diagnostic Markers and Evaluation * **Natriuretic Peptides:** BNP ($\ge 35$ pg/mL) or NT-proBNP ($> 125$ pg/mL) are useful to support or exclude a diagnosis of HF. Levels may be lower in patients with obesity. * **Filling Pressures:** Evidence of increased filling pressures can be obtained noninvasively (Doppler echocardiography) or invasively (hemodynamic measurement). * **Initial Testing:** Includes 12-lead ECG, complete blood count, urinalysis, electrolytes, renal function (BUN/Creatinine), glucose, lipid profile, liver function, iron studies, and thyroid-stimulating hormone (TSH). * **Imaging:** Transthoracic echocardiography (TTE) is the preferred initial modality. Chest X-ray assesses heart size and pulmonary congestion. --- ## Short-Answer Practice Questions **Q1: What are the four medication classes now included in GDMT for HFrEF?** *Answer:* The four classes are ACEi, ARB, or ARNi; beta blockers; mineralocorticoid receptor antagonists (MRAs); and sodium-glucose cotransporter-2 inhibitors (SGLT2i). **Q2: How is "Heart Failure with Improved Ejection Fraction" (HFimpEF) defined?** *Answer:* It refers to patients who previously had HFrEF (LVEF $\le 40\%$) but now have a follow-up LVEF measurement of $> 40\%$. **Q3: What are the blood pressure targets recommended for patients in Stage A (At Risk for HF)?** *Answer:* Blood pressure should be controlled in accordance with GDMT for hypertension, specifically aiming for a goal of $< 130/80$ mm Hg in those with a cardiovascular disease (CVD) risk of $\ge 10\%$. **Q4: Under what circumstances is an Implantable Cardioverter-Defibrillator (ICD) recommended for primary prevention in Stage B (Pre-HF)?** *Answer:* An ICD is recommended for patients who are at least 40 days post-myocardial infarction (MI) with an LVEF $\le 30\%$ and NYHA class I symptoms, provided they are on GDMT and have a life expectancy of $> 1$ year. **Q5: Which medications should be avoided or are considered potentially harmful in patients with an LVEF $< 50\%$?** *Answer:* Thiazolidinediones (increased risk of HF hospitalization) and non-dihydropyridine calcium channel blockers with negative inotropic effects. **Q6: What diagnostic score can help differentiate HFpEF from noncardiac causes of dyspnea?** *Answer:* The $H_2FPEF$ score, which integrates variables like obesity, atrial fibrillation, age $> 60$, antihypertensive use, and echocardiographic parameters. --- ## Essay Prompts for Deeper Exploration 1. **The Shift in Primary Prevention:** Analyze the clinical significance of renaming Stage A and Stage B to "At Risk for HF" and "Pre-HF." How does this terminology change impact clinician behavior and patient education regarding the progression of cardiovascular disease? 2. **Racial and Ethnic Disparities in HF Outcomes:** The guideline notes that non-Hispanic Black patients have the highest HF death rates and higher hospitalization rates despite a faster decline in HF incidence compared to White patients. Discuss the potential social determinants of health and policy changes required to address these inequities in HF care. 3. **The Evolving Role of SGLT2 Inhibitors:** SGLT2i were originally used for glucose lowering but now hold Class 1 recommendations for HF prevention in diabetic patients and for HFrEF treatment. Evaluate the evidence for their use in HFmrEF and HFpEF as presented in the 2022 guideline updates. 4. **Diagnostic Complexity of HFpEF:** Explain why diagnosing HF with preserved ejection fraction is often more challenging than diagnosing HFrEF. Detail the role of biomarkers, exercise stress testing, and invasive hemodynamics in confirming the diagnosis. --- ## Glossary of Important Terms * **ACEi (Angiotensin-Converting Enzyme Inhibitors):** A class of medication used to prevent symptomatic HF and reduce mortality, especially in HFrEF and post-MI. * **ARNi (Angiotensin Receptor-Neprilysin Inhibitors):** A combination therapy (e.g., sacubitril/valsartan) that is a first-line component of GDMT for HFrEF. * **BNP (B-type Natriuretic Peptide):** A biomarker secreted by the heart in response to stretch or injury; used for diagnosis, risk stratification, and establishing prognosis. * **Cardiac Amyloidosis:** An infiltrative heart disease requiring specific diagnostic screening (serum/urine light chains, bone scintigraphy) and specialized treatment. * **CMR (Cardiac Magnetic Resonance):** An imaging modality used for accurate assessment of volumes and EF, as well as myocardial characterization to identify causes like sarcoidosis or myocarditis. * **CPET (Cardiopulmonary Exercise Testing):** The gold standard for quantifying exercise capacity and determining the appropriateness of advanced therapies like heart transplant or LVAD. * **GDMT (Guideline-Directed Medical Therapy):** The optimal framework for clinical evaluation, diagnostic testing, and pharmacological/procedural treatments as defined by evidence-based guidelines. * **LVEF (Left Ventricular Ejection Fraction):** The percentage of blood pumped out of the left ventricle with each contraction; the primary metric for HF classification. * **NYHA Functional Classification:** A subjective scale (Class I–IV) used by clinicians to characterize the severity of a patient’s symptoms and functional limitations. * **SGLT2i (Sodium-Glucose Cotransporter-2 Inhibitors):** A class of medications (e.g., empagliflozin, dapagliflozin) that reduces HF hospitalizations and cardiovascular mortality.